IDEAYA Biosciences 将来の成長

Future 基準チェック /26

IDEAYA Biosciences利益と収益がそれぞれ年間21.3%と31.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-32.6% 19.7%なると予測されています。

主要情報

21.3%

収益成長率

19.74%

EPS成長率

Biotechs 収益成長	22.9%
収益成長率	31.2%
将来の株主資本利益率	-32.57%
アナリストカバレッジ	Good
最終更新日	07 Jan 2026

今後の成長に関する最新情報

Recent updates

Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away

Nov 25

We're Keeping An Eye On IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Jul 28

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

Apr 16

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Dec 04

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

Sep 20

Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?

Jul 08

Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

Jun 18

Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Feb 22

Ideaya Biosciences: A Strong Bet In Targeted Oncology

Feb 16

Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Nov 09

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Oct 03

業績と収益の成長予測

NasdaqGS:IDYA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	264	-235	-217	-114	10
12/31/2027	134	-315	-253	-203	16
12/31/2026	52	-331	-309	-287	18
12/31/2025	217	-111	-45	-14	18
9/30/2025	215	-161	-105	-102	N/A
6/30/2025	7	-332	-297	-294	N/A
3/31/2025	7	-307	-268	-264	N/A
12/31/2024	7	-274	-251	-248	N/A
9/30/2024	4	-178	-153	-150	N/A
6/30/2024	12	-154	-134	-131	N/A
3/31/2024	16	-129	-135	-131	N/A
12/31/2023	23	-113	-118	-115	N/A
9/30/2023	23	-103	-116	-115	N/A
6/30/2023	45	-74	-111	-109	N/A
3/31/2023	47	-68	-98	-95	N/A
12/31/2022	51	-59	-91	-87	N/A
9/30/2022	50	-53	-85	-80	N/A
6/30/2022	29	-66	-72	-69	N/A
3/31/2022	32	-55	-64	-62	N/A
12/31/2021	28	-50	-58	-56	N/A
9/30/2021	36	-37	-53	-51	N/A
6/30/2021	36	-30	50	52	N/A
3/31/2021	27	-31	50	51	N/A
12/31/2020	20	-34	55	55	N/A
9/30/2020	9	-40	58	58	N/A
6/30/2020	N/A	-46	-43	-42	N/A
3/31/2020	N/A	-44	-40	-39	N/A
12/31/2019	N/A	-42	-41	-39	N/A
9/30/2019	N/A	-40	-40	-38	N/A
6/30/2019	N/A	-42	N/A	-36	N/A
3/31/2019	N/A	-38	N/A	-32	N/A
12/31/2018	N/A	-34	N/A	-28	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IDYA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IDYA今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: IDYA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: IDYAの収益 ( 31.2% ) US市場 ( 10.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: IDYAの収益 ( 31.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IDYA 3 年以内に赤字になると予測されています。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/01/07 17:18
終値	2026/01/07 00:00
収益	2025/09/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

IDEAYA Biosciences, Inc. 18 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。34

アナリスト	機関
Madhu Kumar	Baird
Zhiqiang Shu	Berenberg
Suranjit Mukherjee	BTIG

IDEAYA Biosciences 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 242%

Consensus revenue estimates increase by 501%

Consensus revenue estimates fall by 32%

Price target decreased by 8.1% to US$46.93

Consensus revenue estimates increase by 22%

Consensus revenue estimates decrease by 53%, EPS upgraded

Recent updates

Insufficient new directors

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (Optimum-02) of Darovasertib in Combination with Crizotinib in First-Line HLA A2-Negative Metastatic Uveal Melanoma

IDE034, a Bispecific ADC Licensed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd to IDEAYA Biosciences, Inc, Receives FDA IND Clearance

Ideaya Biosciences, Inc. Announces Ind Clearance for Ide034, A Potential First-In-Class Bispecific B7h3/Ptk7 Top1 Adc Targeting Multiple Solid Tumor Types

Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 242%

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in A Proffered Paper Oral Presentation At ESMO 2025

IDEAYA Biosciences Announces Positive Data from Phase 1/2 Combination Trial of IDE397, a Potential First-In-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

IDEAYA Biosciences, Inc. Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397

Consensus revenue estimates increase by 501%

IDEAYA Biosciences, Inc. Announces IND Submission for IDE892, A Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors

Ideaya Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma At the 2025 Society for Melanoma Research Congress

Consensus revenue estimates fall by 32%

We're Keeping An Eye On IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

IDEAYA Biosciences, Inc. Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy

Price target decreased by 8.1% to US$46.93

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000 Growth Index

Ideaya Biosciences, Inc. Appoints Joshua Bleharski as Chief Financial Officer

IDEAYA Biosciences, Inc., Annual General Meeting, Jun 24, 2025

Insufficient new directors

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth?

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

Consensus revenue estimates increase by 22%

IDEAYA Biosciences, Inc. Announces Resignation of Susan L. Kelley from the Board

IDEAYA Biosciences, Inc. Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

President exercised options to buy US$278k worth of stock.

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ideaya Biosciences, Inc. Announces the Appointment of Joshua Bleharski as Chief Financial Officer

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming

We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth

IDEAYA Biosciences, Inc. Announces IDMCRecommendation of Move-Forward Dose in Part 2A of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

Ideaya Biosciences, Inc. Announces First-Patient-In for Phase 1 Clinical Trial Evaluating Ide161 in Combination with Keytruda®? (Pembrolizumab) in Patients with Endometrial Cancer

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer

Consensus revenue estimates decrease by 53%, EPS upgraded

Third quarter 2024 earnings released: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)

IDEAYA Biosciences, Inc. Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

IDEAYA Biosciences, Inc. Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

Consensus revenue estimates fall by 32%

First half 2024 earnings released: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

Consensus revenue estimates increase by 10%

IDEAYA Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $263.000016 million.

Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000E Value Index

Chief Legal Officer & Company Secretary exercised options to buy US$1.9m worth of stock.

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences, Inc. Announces Clinical Program Updates for Ide397 A Potential First-In-Class Phase 2 Mat2a Inhibitor Targeting MTAP-Deletion Solid Tumors

Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

Chief Scientific Officer notifies of intention to sell stock

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

President notifies of intention to sell stock

Consensus revenue estimates fall by 28%

First quarter 2024 earnings released: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Price target increased by 12% to US$49.11

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Ideaya Biosciences: A Strong Bet In Targeted Oncology

Principal Accounting Officer notifies of intention to sell stock

Price target increased by 8.2% to US$43.70

Co-Founder notifies of intention to sell stock